

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/021,132	)	Confirmation No.: 2468
	)	
Applicant: Donald E. Bobo, Jr.	)	
	)	
Filed: October 29, 2001	)	
	)	
T.C. / A.U.: 3735	)	
	)	
Examiner: David Shay	)	
	)	
Docket No.: CVG-5637	)	
	)	
Customer No.: 30452	)	
	)	

---

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****APPEAL BRIEF UNDER 37 CFR 41.37**

Mail Stop Appeal Brief-Patents  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Final Office Action mailed February 22, 2007, please consider the Appeal Brief contained herein. It is believed that this Appeal Brief addresses all outstanding issues; that entry of this Appeal Brief is proper; and that the preparation and mailing of an Examiner's Answer is now in order.

The Commissioner is hereby authorized to charge payment of the \$500 fee for filing of this Appeal Brief to Deposit Account No. 50-1225. The Commissioner is authorized to charge any additional filing fees, including any extensions of time fees, or credit any overpayment to Deposit Account No. 50-1225.

Serial No.: 10/021,132  
Docket No.: CVG-5637  
Appeal Brief dated September 6, 2007  
Responsive to the FINAL Office Action dated February 22, 2007

#### **REAL PARTY IN INTEREST**

The real party in interest is Edwards Lifesciences Corporation, a California corporation having a place of business at One Edwards Way, Irvine, CA 92614-5686. Edwards Lifesciences Corporation is the Assignee of all rights in the application.

#### **RELATED APPEALS AND INTERFERENCES**

There are currently no appeals or interferences known to the appellant, the appellant's legal representative, or assignee which will directly affect or be directly affected by or have a bearing on the Board's decision in the pending appeal.

#### **STATUS OF CLAIMS**

Claims 36-44 are currently pending and of these claims, claims 36, 39 and 42 are independent. Claims 1-35 and 45 have been previously canceled. Claims 36-44 are rejected. Claims 36-44 are currently being appealed.

#### **STATUS OF AMENDMENTS**

No amendments have been filed subsequent to final rejection. The claims as they are currently entered are presented in the Appendix of this document.

#### **SUMMARY OF CLAIMED SUBJECT MATTER**

Claims 36, 39 and 42 of the appealed claims 26-44 are independent and the remaining claims depend from one of these three claims.

In accordance with 37 C.F.R. 41.37(c)(1)(v) the subject matter of independent claims 36, 39 and 42 is concisely explained below. It is believed that none of these independent claims includes means plus function or step plus function wording.

The subject matter as defined in claim 36 involved in this appeal relates to a method for delivering medicament to tissue in a chamber of the heart with a delivery device while traversing a right atrium and sealably traversing an atrial septum. As shown in one example embodiment in FIG. 42a, the delivery device 300' comprises a deflated first balloon 316a and a deflated second balloon 316b in communication with at least one internal inflation lumen 318. The device 300' is advanced to a position proximate the area of interest, such as an atrial septum, and a hole 320 is formed in the tissue 308a.

As shown in FIG. 42b, the distal portion of the device 300' and the deflated second balloon 316b is advanced therethrough. Thereafter, the first balloon 316a and the second balloon 316b are inflated, thereby supportively engaging the tissue 308a disposed therebetween. Thereafter the device 300' is advanced to and engages tissue 308b. As seen in FIG. 42c, a tissue ablating member 310 is positioned on the distal end of the device for creating a channel through the surface of the tissue 308b. Once the channel is created, medicament is delivered to the channel, for example, through a port on the distal end of the device.

The subject matter as defined in claim 39 involved in this appeal relates to a method of delivering medicament to tissue while preventing medicament washout. As seen in FIGS. 41a-41c, a delivery device 300' is advanced to a tissue surface so that the distal end of the delivery device 300' is proximate the tissue surface.

As shown in FIG. 41a, the device 300' comprises at least one vacuum port 312' positioned radially about the tissue-engaging surface 306' and in communication with at least one vacuum lumen 314' located within the device 300' to engage the tissue 308'. The device is advanced to a position proximal the tissue 308. An external vacuum source (not shown) is activated and a vacuum force is transmitted to the at least one vacuum port 312' through the vacuum lumen 314'.

Thereafter, the device 300' is advanced to engage the tissue 308, resulting in tissue 308 being retained and sealed by the device 300'. The ablating member 310' may then be advanced into the tissue 308 to create a channel in the tissue 308. FIG. 41b shows an embodiment of the present invention retaining a portion of tissue 308' and advancing the ablating member 310'

therein. FIG. 41c shows the distal portion of an embodiment of the present invention comprising a tissue ablating member 310 positioned thereon and having four vacuum ports 312a-d positioned on the tissue-engaging surface 306. The medicament is then delivered into the channel and prevented from passing between the tissue-engaging surface 306 and the tissue 308.

The subject matter as defined in claim 42 involved in this appeal relates to a method of delivering medicament to tissue while preventing medicament washout.

As illustrated in FIG. 43a-43c, a distal end of the device 300' is advanced to the surface of tissue 308'. The distal portion of the device 300' further comprises at least one sealing balloon 330 in communication with at least one internal inflation lumen 318'. As shown in FIG. 43, the distal portion of device 300' is positioned proximate the tissue 308'. The at least one sealing balloon 330 is inflated and sealably engages the tissue 308'. Thereafter, a tissue channel 332 is formed by advancing the ablating member 334 into the tissue 308'. A medicament, for example an angiogenesis-inducing agent, may be applied through port 336 to the tissue 308' forming the channel 332. The at least one sealing balloon 330 prevents medicament washout by sealing the tissue channel 332.

### **GROUND OF REJECTION TO BE REVIEWED ON APPEAL**

#### **I. GROUND 1 – REJECTION OF CLAIMS 36-38 UNDER SECTION 112**

The first ground of rejection to be reviewed on appeal is the Examiner's rejection of claims 36-38 under 35 U.S.C. Section 112, first paragraph. The Examiner contends that the specification does not support "supportively engaging the medicament delivery catheter with the atrial septum" as claimed in claim 36.

Serial No.: 10/021,132  
Docket No.: CVG-5637  
Appeal Brief dated September 6, 2007  
Responsive to the FINAL Office Action dated February 22, 2007

**II. GROUND 2 – REJECTION OF CLAIMS 36-38 UNDER SECTION 112**

The second ground of rejection to be reviewed on appeal is the Examiner's rejection of claims 36-38 under 35 U.S.C. Section 112, first paragraph. The Examiner contends that the specification does not support a "medicament delivery catheter."

**III. GROUND 3 – REJECTION OF CLAIMS 42-44 UNDER SECTION 102**

The third ground of rejection to be reviewed on appeal is the Examiner's rejection of Claims 42-44 under 35 U.S.C. Section 102(e) as being anticipated by U.S. Patent No. 6,283,951 to Flaherty et al. (*Flaherty et al.*).

**IV. GROUND 4 – REJECTION OF CLAIMS 36-38 UNDER SECTION 103**

Claims 36-38 are rejected under 35 U.S.C. Section 103(a) as being anticipated by U.S. Patent No. 6,283,951 to Flaherty et al. (*Flaherty et al.*) in combination with U.S. Patent No. 6,645,199 to Jenkins et al. (*Jenkins et al.*), U.S. Patent No. 6,161,543 to Cox et al. (*Cox et al.*) and U.S. Patent Application No. 2001/0049497 to Kalloo et al. (*Kalloo et al.*).

**V. GROUND 5 – REJECTION OF CLAIMS 39 AND 40 UNDER SECTION 103**

Claims 39 and 40 are rejected under 35 U.S.C. Section 103(a) as being anticipated by *Flaherty et al.* in combination with *Jenkins et al.*, and U.S. Patent No. 5,725,523 to Mueller (*Mueller*).

**VI. GROUND 5 – REJECTION OF CLAIM 41 UNDER SECTION 103**

Claim 41 is rejected under 35 U.S.C. Section 103(a) as being anticipated by *Flaherty et al.* in combination with *Jenkins et al.*, and *Mueller* in further view of U.S. Patent No. 5,607,421 to Jeevanandam et al. (*Jeevanandam et al.*).

## ARGUMENT

### I. GROUND 1 – REJECTION OF CLAIMS 36-38 UNDER SECTION 112

The Examiner rejects claims 36-38 under 35 U.S.C. Section 112, first paragraph and contends that the specification does not support “supportively engaging the medicament delivery catheter with the atrial septum” as claimed in claim 36.

Section 2163.02 of the M.P.E.P. best describes the legal standards for a section 112, first paragraph rejection as follows:

The courts have described the essential question to be addressed in a description requirement issue in a variety of ways. An objective standard for determining compliance with the written description requirement is, "does the description clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed." *In re Gosteli*, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989). Under *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991), to satisfy the written description requirement, an Applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention, and that the invention, in that context, is whatever is now claimed. The test for sufficiency of support in a parent application is whether the disclosure of the application relied upon "reasonably conveys to the artisan that the inventor had possession at that time of the later claimed subject matter." *Ralston Purina Co. v. Far-Mar-Co., Inc.*, 772 F.2d 1570, 1575, 227 USPQ 177, 179 (Fed. Cir. 1985) (quoting *In re Kaslow*, 707 F.2d 1366, 1375, 217 USPQ 1089, 1096 (Fed. Cir. 1983)).

Whenever the issue arises, the fundamental factual inquiry is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, Applicant was in possession of the invention as now claimed. See, e.g., *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991). An Applicant shows possession of the claimed invention by describing the claimed invention with all of its limitations using such descriptive means as words, structures, figures, diagrams, and formulas that fully set forth the claimed invention. *Lockwood v. American Airlines, Inc.*, 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (Fed. Cir. 1997). Possession may be shown in a variety of ways including description of an actual reduction to practice, or by showing that the invention was "ready for patenting" such as by the disclosure of drawings or structural chemical formulas that show

that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that the Applicant was in possession of the claimed invention. See, e.g., *Pfaff v. Wells Elecs., Inc.*, 525 U.S. 55, 68, 119 S.Ct. 304, 312, 48 USPQ2d 1641, 1647 (1998); *Regents of the University of California v. Eli Lilly*, 119 F.3d 1559, 1568, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997); *Amgen, Inc. v. Chugai Pharmaceutical*, 927 F.2d 1200, 1206, 18 USPQ2d 1016, 1021 (Fed. Cir. 1991) (one must define a compound by "whatever characteristics sufficiently distinguish it").

The subject matter of the claim need not be described literally (i.e., using the same terms or *in haec verba*) in order for the disclosure to satisfy the description requirement. If a claim is amended to include subject matter, limitations, or terminology not present in the application as filed, involving a departure from, addition to, or deletion from the disclosure of the application as filed, the examiner should conclude that the claimed subject matter is not described in that application. This conclusion will result in the rejection of the claims affected under 35 U.S.C.112, first paragraph - description requirement, or denial of the benefit of the filing date of a previously filed application, as appropriate.

As previously stated in the Amendment filed November 30, 2006, this language is no longer present in independent claim 36 (and thereby dependent claims 37-38). Claim 36 was amended to recite, in part, "supportively engaging the atrial septum at the opening with the medicament delivery catheter". Support for this recited language can be found in paragraph 0151 of the present Application which states:

[0151] An alternate embodiment of the present invention is illustrated in FIG. 42a-42c. As shown in FIG. 42a, the device 300' comprises a deflated first balloon 316a and a deflated second balloon 316b in communication with at least one internal inflation lumen 318. The device 300' is advanced to a position proximate the area of interest and a hole 320 is formed in the tissue 308a. As shown in FIG. 42b, the distal portion of the device 300' and the deflated second balloon 316b is advanced therethrough. **Thereafter, the first balloon 316a and the second balloon 316b are inflated, thereby supportively engaging the tissue 308a disposed therebetween**. Thereafter the device 300' is advanced to and engages tissue 308b. Those skilled in the art will appreciate the present embodiment may be used to isolate discrete portion of tissue or organs. **For example, the present invention may be utilized to sealably traverse the atrial septum and precisely ablate and inject medicament to an isolated chamber of the heart**. FIG. 42c shows the distal portion of the present invention comprising a

tissue ablating member 310 and having a first and second balloon 316a-b positioned thereon. [Emphasis added]

Since the specification and claim 36 recite nearly identical terms and language, it is believed that the language of claims 36-38, and specifically the recited language “supportively engaging the atrial septum at the opening with the medicament delivery catheter” conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, the Applicant was in possession of the invention as now claimed. Therefore, it is submitted that these claims are properly supported under Section 112, first paragraph and the legal standards summarized in Section 2163.02 of the M.P.E.P. It is therefore respectfully requested that this rejection of claims 36-38 be withdrawn.

## **II. GROUND 2 – REJECTION OF CLAIMS 36-38 UNDER SECTION 112**

The second ground of rejection to be reviewed on appeal is the Examiner’s rejection of claims 36-38 under 35 U.S.C. Section 112, first paragraph. The Examiner contends that the specification does not support a “medicament delivery catheter”.

As previously reproduced in the discussion of the first grounds of rejection, Section 2163.02 of the M.P.E.P. best describes the legal standards for a section 112, first paragraph rejection. For example, “the fundamental factual inquiry is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, Applicant was in possession of the invention as now claimed.”

Numerous embodiments of the invention described in the present Application provide support for the device being in catheter form. For example, paragraph 0087, “...handpiece 54 may be a flexible catheter...”; paragraph 0090, “...handpiece 54 such as a catheter...”; paragraph 0113, “When handpiece 54 is configured as a catheter...”; paragraph 0140, “System 230 includes an ablating and injecting device 232 received within a catheter 234...”; paragraph 0141, “...guiding the ablating and injecting device 232 and catheter 234...”; and paragraph



Serial No.: 10/021,132  
Docket No.: CVG-5637  
Appeal Brief dated September 6, 2007  
Responsive to the FINAL Office Action dated February 22, 2007


0153, "...the present embodiment permits catheter-based delivery of the ablation and injection system..." to name just a few examples.

Since the specification and claim 36 clearly describe the use of the present invention as a "medicament delivery catheter" it is submitted that claims 36-38 convey with reasonable clarity to those skilled in the art that, as of the filing date sought, Applicant was in possession of the invention as now claimed. Therefore, these claims are properly supported under Section 112, first paragraph and the legal standards summarized in Section 2163.02 of the M.P.E.P.. It is therefore requested that this rejection of claims 36-38 be withdrawn.

### III. GROUND 3 – REJECTION OF CLAIMS 42-44 UNDER SECTION 102

The rejection of Claims 42-44 is maintained under 35 U.S.C. Section 102(e) as being anticipated by *Flaherty et al.*

Claim 42 is directed to a method of delivering medicament to tissue while preventing medicament washout, comprising: providing a medicament delivery catheter having a tissue engaging surface with a sealing balloon; providing access to a tissue surface; advancing the catheter to the tissue surface; positioning the tissue engaging surface proximate the tissue surface; sealably engaging the tissue engaging surface to the tissue surface by inflating the sealing balloon; forming a sealed opening in the tissue surface; delivering medicament through the sealed opening in the tissue surface; and, preventing the medicament from passing between the tissue engaging surface and the tissue surface to a location outside of the sealed opening.



**FIG. 6**

As seen in Figure 6 above, *Flaherty et al.* discloses a porous drug delivery balloon 218 for infusing a drug in a predetermined pattern within the tissue 220. “The porous balloon 218 includes a porous region, such as a plurality of holes 226, a permeable membrane and the like, preferably arranged to provide a predetermined flow pattern through the balloon 218 into the tissue region 220,” Col 13, lines 48-52, *Flaherty et al.*

In response to the Applicant’s arguments that *Flaherty et al.* does not show “sealing” as recited in claim 42 (see the Amendment dated March 27, 2006), the Examiner asserted in the June 30, 2006 Office Action that:

The balloon of *Flaherty et al.* clearly performs a sealing function, as it pushes against the tissue to distend it. Thus it is unclear how Applicant can assert that the balloon does not seal the tissue when pressure is applied thereto by the balloon from maintaining pressure. The mere fact that medicament can leak out slowly does not prevent the balloon from maintaining pressure.

In response to the Applicant’s further arguments that *Flaherty et al.* does not show “sealing” as recited in claim 42 (see the Amendment dated November 30, 2006), the Examiner asserted in the February 22, 2007 Office Action that *Flaherty et al.* “...expressly teaches that the

balloon need not be porous (see column 2, lines 11-18). Thus the balloon of *Flaherty et al.* clearly seals the passage.”

Column 2, lines 11-14 of *Flaherty et al.* states:

As an alternative to perfusion balloons and/or infusion catheters, a drug may be embedded in or deposited on a catheter, e.g. in the catheter wall, the wall of a non-porous balloon on the catheter, and/or a coating on the catheter.

The Examiner implies that this statement means that *Flaherty et al.* is stating that the porous drug delivery balloon 218 may alternately be non-porous. However, this implicit assertion is misleading because the “non-porous” statement of column 2 is located in the Background section of *Flaherty et al.* and is referring to drug delivery methods known in the art. Thus, in the context of the Background, this citation states that the deliver of drugs imbedded in the wall of a non-porous balloon is known in the prior art. Therefore, *Flaherty et al.* does not disclose that the porous drug delivery balloon 218 can be non-porous.

Further, in the June 30, 2006 Office Action the Examiner acknowledged that medicament can “leak out” from a tissue opening of the *Flaherty et al.* device by way of the porous drug delivery balloon 218 but incongruously argued that the porous balloon can somehow seal an opening despite these holes. This assertion ignores the meaning of the word “sealably” as used in claim 42.

For example, a common definition of “seal” according to the 2006 Encarta World English Dictionary is, “a tight closure that prevents the entrance or escape of, e.g. air or water, or a substance or device that forms such a closure.” While this exemplary definition is not meant to be limiting, it does emphasize the importance of preventing entrance or escape of a substance. In contrast, the *Flaherty et al.* device is specifically intended to encourage the escape or passage of medicament through the porous balloon, thereby preventing the *Flaherty et al.* porous balloon from sealably engaging a tissue engaging surface to the tissue surface. Thus, *Flaherty et al.* does not disclose sealably engaging the tissue as recited in claim 42.

Further, even if the porous balloon of the *Flaherty et al.* device could somehow be considered to seal, it does not prevent the medicament from passing between the tissue engaging surface and the tissue surface to a location outside of the sealed opening as recited in claim 42. As previously discussed, the porous drug delivery balloon 218 encourages the escape or passage of medicament through the holes or pores in the balloon's surface.

Thus, for at least these reasons, it is respectfully requested that the Section 102(e) rejection against claim 42 be withdrawn.

Turning to claim 43, this claim depends from claim 42 and is further directed to maintaining the inflated balloon against the tissue surface while the opening is formed.

*Flaherty et al.* uses a puncturing element 14 (seen in Figure 6) to puncture the tissue 220. The drug delivery catheter 214 may be deployed over the puncturing element 14 and finally the porous drug delivery balloon 218 can be inflated with drugs. In other words, the opening in *Flaherty et al.* is formed first, then the drug delivery catheter 214 is positioned and finally the porous drug delivery balloon 218 is inflated with drugs. Thus, *Flaherty et al.* does not disclose maintaining the inflated balloon against the tissue surface while the opening is formed. Thus, for at least these reasons and the reasons set forth for claim 42, it is requested that the Section 102(e) rejection against claim 43 be withdrawn.

Turning to claim 44, this claim depends from claim 42 and further includes that the inflated balloon is maintained against the tissue opening while the medicament is delivered. However, *Flaherty et al.* (e.g., Id., Fig. 6) only discloses inflating the porous drug delivery balloon within the channel created by the puncturing element 14, not against the tissue opening. Since the porous drug delivery balloon is delivering drugs, it is desirable for it to be positioned deep within the tissue to similarly deliver drugs deep within the tissue. In contrast, it is desirable for the present invention as recited in claim 44 to seal the tissue opening to allow drugs to enter and remain in the tissue while preventing medicament washout. Thus, for at least these reasons and the reasons set forth for claim 42, it is requested that the Section 102(e) rejection against claim 43 be withdrawn.

IV. GROUND 4 – REJECTION OF CLAIMS 36-38 UNDER SECTION 103

Claims 36-38 are rejected under 35 U.S.C. Section 103(a) as being anticipated by *Flaherty et al.* in combination with *Jenkins et al.*, *Cox et al.* and *Kalloo et al.*

Claim 36 is directed to a method of delivering medicament to tissue in a chamber of the heart while traversing a right atrium and sealably traversing an atrial septum, comprising: introducing a medicament delivery catheter through an endoluminal entry point and advancing the catheter through a circulatory system; directing the catheter to traverse the right atrium and puncture the atrial septum of a patient to form an opening; supportively engaging the atrial septum at the opening with the medicament delivery catheter; sealing the opening with the medicament delivery catheter; further advancing the medicament delivery catheter through the sealed opening to a surface on the chamber of the heart; and creating a channel through the surface of the heart chamber and delivering medicament into the channel.

The combined references as asserted by the Examiner do not show or render obvious the present invention as recited in claims 36-38. For example, *Flaherty et al.* does not teach supportively engaging the atrial septum at an opening with the medicament delivery catheter and sealing the opening with the medicament delivery catheter.

To remedy this deficiency, the Examiner asserts that “Cox et al teach the use of means to seal the tissue around an internal chamber ablation device to prevent bleeding when working on a bleeding heart.” However, as seen in column 27, lines 9-21 of *Cox et al.*, the “means to seal” is performed with sutures, staples or a clamp (i.e., devices distinct from the catheter and which are not delivered by the catheter). In other words, the sealing taught in *Cox et al.* requires additional tools and distinct devices which are not integrated into a single method as in the presently claimed invention. Thus, contrary to the Examiner’s assertion, *Cox et al.* does not show supportively engaging the atrial septum at an opening with the medicament delivery catheter and sealing the opening with the medicament delivery catheter as claimed.

*Nor does Kalloo et al.* make up for this deficiency. The Examiner asserts that “Kalloo et al teach the use of a dual balloon stabilizing means to aid in the placement of a surgical device.”

However, simply combining the balloons of *Kalloo et al.* will not achieve the invention as recited in claim 36. The device of *Kalloo et al.* is directed to performing a procedure within a stomach with an endoscope (transgastric peritoneoscopy).

While the device of *Kalloo et al.* may include balloons, these balloons are not appropriate for use with the present invention as claimed. For example, the *Kalloo* balloons are sized and configured for use on an endoscope during entry into a stomach and therefore include a relatively large diameter, large thickness and greater distance between both balloons. Simply placing these *Kalloo* balloons on a device appropriately sized for a cardiac procedure as the Examiner suggests will not result in a device that can engage and seal an atrial septum as claimed in claim 36 without some additional teaching as to how such an adaptation may be performed. The atrial septum is small and relatively delicate, requiring different design considerations than the larger and more rugged entry into the stomach.

Nor does *Jenkins et al.* make up for this deficiency. *Jenkins et al.* is directed to a method of pushing an electrode loop with an expandable structure to create a circumferential lesion to treat atrial fibrillation. While *Jenkins et al.* may suggest a maize technique for ablating a portion of the heart, it does not make up for the deficiencies of *Flaherty et al.* because it does not teach supportively engaging the atrial septum at an opening with the medicament delivery catheter and sealing the opening with the medicament delivery catheter. In this respect, *Jenkins et al.* fails to teach any type of sealing device and, therefore, does not make up for the deficiency of *Flaherty et al.* and *Mueller*.

Hence it is clear that *Jenkins et al.*, *Cox et al.* and *Kalloo et al.* do not make up for the deficiencies of *Flaherty et al.* Accordingly it is respectfully submitted that the rejection of claims 36-38 should be withdrawn.

#### V. GROUND 5 – REJECTION OF CLAIMS 39 AND 40 UNDER SECTION 103

Claims 39 and 40 are rejected under 35 U.S.C. Section 103(a) as being anticipated by *Flaherty et al.* in combination with *Jenkins et al.*, and *Mueller*.

Claim 39 is directed to a method of delivering medicament to tissue while preventing medicament washout, comprising: providing a medicament delivery catheter having a tissue engaging surface with at least one vacuum operated tissue stabilizer port; providing access to a tissue surface; advancing the catheter to the tissue surface; positioning the tissue engaging surface proximate the tissue surface; sealably engaging the tissue engaging surface to the tissue surface by activating a vacuum force through the tissue stabilizer port; forming a sealed opening in the tissue surface; delivering medicament through the sealed opening in the tissue surface; and preventing the medicament from passing between the tissue engaging surface and the tissue surface to a location outside the sealed opening.

Claim 40 depends on claim 39 and further recites that the catheter comprises at least one vacuum port positioned radially about the tissue engaging surface and at least one vacuum lumen located within the catheter.

The combination of *Flaherty et al.* with *Jenkins et al.* and *Mueller* cannot be properly relied upon to reject claims 39 and 40. For example, *Flaherty et al.* fails to show preventing the medicament from passing between the tissue engaging surface and the tissue surface to a location outside the sealed opening.

*Jenkins et al.* and *Mueller* do not make up for this deficiency in *Flaherty et al.* For example, *Mueller* is directed to a device which creates a seal against an area of tissue by providing suction or a vacuum. This suction, when combined with *Flaherty et al.* would likely cause the medicament within the porous balloon to be drawn out and sucked up by the vacuum, reducing the pressure in the porous balloon and preventing the creation of a seal. Thus, medicament may pass between the balloon and the tissue surface.

Moreover, *Jenkins et al.* is directed to a method of pushing an electrode loop with an expandable structure to create a circumferential lesion to treat atrial fibrillation. In this respect, *Jenkins et al.* fails to teach any type of sealing device and therefore does not make up for the deficiency of *Flaherty et al.* and *Mueller*. Hence, again it is shown that the rejection of claims

39 40 based on the combination of *Flaherty et al.* with *Jenkins et al.* and *Mueller* is improper and should be withdrawn.

**VI. GROUND 5 – REJECTION OF CLAIM 41 UNDER SECTION 103**

Claim 41 is rejected under 35 U.S.C. Section 103(a) as being anticipated by *Flaherty et al.* in combination with *Jenkins et al.*, *Mueller* in further view of *Jeevanandam et al.*

Claim 41 depends from claim 40 and further comprises four vacuum ports positioned on the tissue engaging surface. The Examiner asserts a similar rejection as set forth in Ground 4, and further cites the *Jeevanandam et al.* as teaching multiple vacuum ports. The arguments presented with regard to claims 39 and 40 in Ground 4 are equally applicable to claim 41. Further, *Jeevanandam et al.* does not teach multiple vacuum ports as asserted by the examiner. As provided in column 5 lines 5-10 of *Jeevanandam et al.*, the device includes three suction cups 44 to stabilize the device:

As shown in FIG. 2B the insertable end 24 of the device has gripping means extending therefrom in the form of three suction cups 44. These cups 44 provide a means to removably mount and stabilize the insertable end 24 to the inner ventricular wall, and serve as a tripod for the end 24, and the fiber end 32.

Suction cups are often concave structures that adhere to a surface. In contrast, the vacuum ports recited in claim 41 connect to a vacuum source, allowing a user to selectively create or disperse a vacuum at the end of the ports. Thus, *Jeevanandam et al.* does not disclose four vacuum ports positioned on the tissue engaging surface as asserted by the Examiner. For at least these reasons it is believed the Section 103 rejection of claim 41 should be withdrawn.



Serial No.: 10/021,132  
Docket No.: CVG-5637  
Appeal Brief dated September 6, 2007  
Responsive to the FINAL Office Action dated February 22, 2007

#### IV. CONCLUSION

For all the reasons stated herein, it is submitted that the Examiner's rejection is erroneous. As a result, the Applicant seeks a reversal of the Examiner's rejection on this appeal. Reversal is hereby affirmatively requested.

Respectfully submitted,

/Rajiv Yadav, Reg. No. 43,999/

Dated: September 6, 2007

---

Rajiv Yadav, Ph.D., Esq.  
Registration No. 43,999  
Edwards Lifesciences LLC  
One Edwards Way, Legal Department  
Irvine, California 92614  
Telephone: (949) 250-6801  
Facsimile: (949) 250-6850

CLAIMS APPENDIX

1-35 (Canceled)

36. (Previously Presented) A method of delivering medicament to tissue in a chamber of the heart while traversing a right atrium and sealably traversing an atrial septum, comprising:

introducing a medicament delivery catheter through an endoluminal entry point and advancing the catheter through a circulatory system;

directing the catheter to traverse the right atrium and puncture the atrial septum of a patient to form an opening;

supportively engaging the atrial septum at the opening with the medicament delivery catheter;

sealing the opening with the medicament delivery catheter;

further advancing the medicament delivery catheter through the sealed opening to a surface on the chamber of the heart; and

creating a channel through the surface of the heart chamber and delivering medicament into the channel.

37. (Previously Presented) The method of claim 36 wherein the catheter comprises a first balloon and a second balloon and supportively engaging the atrial septum at the opening with the medicament delivery catheter comprises inflating a first balloon of the catheter on a proximal side of the opening and inflating a second balloon of the catheter on a distal side of the opening.

38. (Original) The method of claim 37 wherein the atrial septum is received between the first balloon and the second balloon and supported by the inflated first balloon and second balloon.

39. (Previously Presented) A method of delivering medicament to tissue while preventing medicament washout, comprising:

- providing a medicament delivery catheter having a tissue engaging surface with at least one vacuum operated tissue stabilizer port;

- providing access to a tissue surface;

- advancing the catheter to the tissue surface;

- positioning the tissue engaging surface proximate the tissue surface;

- sealably engaging the tissue engaging surface to the tissue surface by activating a vacuum force through the tissue stabilizer port;

- forming a sealed opening in the tissue surface;

- delivering medicament through the sealed opening in the tissue surface; and

- preventing the medicament from passing between the tissue engaging surface and the tissue surface to a location outside the sealed opening.

40. (Original) The method of claim 39 wherein the catheter comprises at least one vacuum port positioned radially about the tissue engaging surface and at least one vacuum lumen located within the catheter.

41. (Original) The method of claim 40 wherein the catheter comprises four vacuum ports positioned on the tissue engaging surface.

42. (Previously Presented) A method of delivering medicament to tissue while preventing medicament washout, comprising:

- providing a medicament delivery catheter having a tissue engaging surface with a sealing balloon;

providing access to a tissue surface;  
advancing the catheter to the tissue surface;  
positioning the tissue engaging surface proximate the tissue surface;  
sealably engaging the tissue engaging surface to the tissue surface by inflating the sealing balloon;  
forming a sealed opening in the tissue surface;  
delivering medicament through the sealed opening in the tissue surface; and,  
preventing the medicament from passing between the tissue engaging surface and the tissue surface to a location outside of the sealed opening.

43. (Original) The method of claim 42 wherein forming a sealed opening in the tissue surface comprises maintaining the inflated balloon against the tissue surface while the opening is formed.

44. (Original) The method of claim 42 wherein the inflated balloon is maintained against the tissue opening while the medicament is delivered.

45. (Canceled)

Serial No.: 10/021,132  
Docket No.: CVG-5637  
Appeal Brief dated September 6, 2007  
Responsive to the FINAL Office Action dated February 22, 2007

**EVIDENCE APPENDIX**

No evidence is submitted pursuant to 37 C.F.R. §§ 1.130-1.132

This Appeal Brief is believed to be fully conforming with the applicable rules and statutes and is in condition for consideration by the Examiner and response thereto. Appellant requests that this patent application be remanded to the Examiner with instructions to withdraw the outstanding rejections and allow the appealed claims.

Serial No.: 10/021,132  
Docket No.: CVG-5637  
Appeal Brief dated September 6, 2007  
Responsive to the FINAL Office Action dated February 22, 2007

**RELATED PROCEEDINGS APPENDIX**

It is believed that there are no proceedings related to the present Application.